Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic ...

Keymed Biosciences announces NMPA approval of Stapokibart, an anti-IL-4Rα monoclonal antibody, for treating chronic rhinosinusitis with nasal polyposis. Positive phase III clinical trial results show significant improvements in nasal symptoms and quality of life.